Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NextCure

NextCure
2015 FOUNDED
PUBLIC STATUS
41-50 EMPLOYEES
NXTC STOCK SYMBOL
$27.12 SHARE PRICE (As of Friday Closing)
Description

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is a immunomedicine against a immunomodulatory receptor called Siglec-15, or S15.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 9000 Virginia Manor Road
  • Suite 200
  • Beltsville, MD 20705
  • United States

+1 (240) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NextCure’s full profile, request a free trial.

NextCure Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$13.86 - $44.69 $616M $26.85 -$3.17 86.5K 22.7M

NextCure Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
Enterprise Value 381,941
Revenue 2,759 0 0
EBITDA (24,889) (21,122) (14,887)
Net Income (26,948) (22,799) (15,469)
Total Assets 213,050 147,628 19,467
Total Debt 5,000 460 860
Public Fundamental Data provided by Morningstar, Inc. disclaimer

NextCure Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore NextCure‘s full profile, request access.

Request full access to PitchBook

NextCure Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore NextCure‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

NextCure Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN 00 000.00 0000000000 0 000.00
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000000 00000
000000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
To view this company’s complete list of competitors, request access »

NextCure Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore NextCure‘s full profile, request access.

Request full access to PitchBook

NextCure Executive Team (9)

Name Title Board
Seat
Contact
Info
Michael Richman Chief Executive Officer & Board Member
Steven Cobourn Chief Financial Officer
Solomon Langermann Ph.D Chief Scientific Officer
James Bingham Ph.D Executive
Lieping Chen Ph.D Co-Founder

1 Former Executive

You’re viewing 5 of 9 executives. Get the full list »

NextCure Board Members (10)

Name Representing Role Since Contact
Info
Briggs Morrison MD Self Board Member 000 0000
Chau Khuong OrbiMed Board Member 000 0000
David Kabakoff Ph.D Sofinnova Investments Chairman 000 0000
Elaine Jones Ph.D Pfizer Ventures Board Member 000 0000
Judith Li Lilly Asia Ventures Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »